Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 3/20 | 0.41 |
| ▸ | HTR2A | P28223 | 5/20 | 0.40 |
| ▸ | HTR2C | P28335 | 3/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 4/20 | 0.38 |
| ▸ | BTK | Q06187 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29536029 | 1.00 | CDC7 (0.41) | CDC7HTR2AHTR2CKDRSYK | |
| SCHEMBL29536009 | 0.90 | MAOB (0.39) | SYKROCK2CCR2ROCK1GRM5 | |
| SCHEMBL22688255 | 0.90 | MAOB (0.39) | SYKROCK2CCR2ROCK1GRM5 | |
| SCHEMBL26321523 | 0.90 | ALDH1A1 (0.38) | CDC7SYKBTKROCK2CCR2 | |
| SCHEMBL22655827 | 0.88 | CDC7 (0.39) | CDC7HTR2AHTR2CKDRSYK | |
| SCHEMBL21900955 | 0.88 | PDGFRB (0.36) | SYKROCK2ROCK1GRM5PIK3CA | |
| SCHEMBL21901248 | 0.86 | GRM5 (0.37) | CDC7GRM5MKNK1PIK3CA | |
| SCHEMBL21901866 | 0.86 | CDC7 (0.40) | CDC7HTR2AHTR2CKDRSYK | |
| SCHEMBL23887925 | 0.85 | MKNK1 (0.37) | KDRSYKROCK2ROCK1MKNK1 | |
| SCHEMBL22688258 | 0.85 | CDC7 (0.36) | CDC7HTR2AHTR2CKDRSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279010-A1 | PROCESSES FOR PREPARING MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-09-07 | — | — | US | claimed |
| CN-116234809-A | Methods of preparing alpha-1 antitrypsin modulators | 弗特克斯药品有限公司 | 2023-06-06 | — | — | CN | claimed |
| EP-3969440-A1 | CONDENSED TRICYCLIC PYRROLES AS ALPHA-1 ANTITRYPSIN MODULATORS | Vertex Pharmaceuticals Incorporated (US) | 2022-03-23 | — | — | EP | claimed |
| CN-114096542-A | Condensed tricyclic pyrroles as alpha-1 antitrypsin modulators | 弗特克斯药品有限公司 | 2022-02-25 | — | — | CN | claimed |
| WO-2020247160-A1 | CONDENSED TRYCICLIC PYRROLES AS ALPHA-1 ANTITRYPSIN MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-12-10 | — | — | WO | claimed |
| US-20200361939-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED. | 2020-11-19 | — | — | US | claimed |
| US-12331057-B2 | Modulators of alpha-1 antitrypsin | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-17 | — | — | US | disclosed |
| US-20240336614-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED | 2024-10-10 | — | — | US | disclosed |
| US-11884672-B2 | Modulators of alpha-1 antitrypsin | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-01-30 | — | — | US | disclosed |
| US-20240002386-A1 | SOLID FORMS OF 4-(5-(4-FLUOROPHENYL)-6-(TETRAHYDRO-2H-PYRAN-4-YL)-1,5-DIHYDROPYRROLO[2,3-F]INDAZOL-7-YL)BENZOIC ACID | VERTEX PHARMA (US) | 2024-01-04 | — | — | US | disclosed |
| CN-116897157-A | Solid forms of 4- (5- (4-fluorophenyl) -6- (tetrahydro-2H-pyran-4-yl) -1, 5-dihydropyrrolo [2,3-F ] indazol-7-yl) benzoic acid | 弗特克斯药品有限公司 | 2023-10-17 | — | — | CN | disclosed |
| US-20230279010-A1 | PROCESSES FOR PREPARING MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-09-07 | — | — | US | disclosed |
| US-20230279010-A1 | PROCESSES FOR PREPARING MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-09-07 | — | — | US | disclosed |
| US-20210179587-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED | 2021-06-17 | — | — | US | disclosed |
| US-20210179587-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED | 2021-06-17 | — | — | US | disclosed |
| WO-2020247160-A1 | CONDENSED TRYCICLIC PYRROLES AS ALPHA-1 ANTITRYPSIN MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-12-10 | — | — | WO | disclosed |
| WO-2020247160-A1 | CONDENSED TRYCICLIC PYRROLES AS ALPHA-1 ANTITRYPSIN MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-12-10 | — | — | WO | disclosed |
| US-20200361939-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED. | 2020-11-19 | — | — | US | disclosed |
| US-20200361939-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED. | 2020-11-19 | — | — | US | disclosed |
| WO-2020081257-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336614-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | SERPINA2, SERPINC1, SERPINA3 | CDC7 3618/4885HTR2A 3839/4885HTR2C 4262/4885 |
| US-11884672-B2 | Modulators of alpha-1 antitrypsin | SERPINA2, SERPINC1, SERPINA3 | CDC7 3618/4885HTR2A 3839/4885HTR2C 4262/4885 |
| US-20230279010-A1 | PROCESSES FOR PREPARING MODULATORS OF ALPHA-1 ANTITRYPSIN | SERPINA2, SERPINC1, SERPINE1 | CDC7 4596/4885HTR2A 3953/4885HTR2C 4604/4885 |
| US-20200361939-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | SERPINA2, SERPINC1, SERPINA3 | CDC7 3618/4885HTR2A 3839/4885HTR2C 4262/4885 |
| US-12331057-B2 | Modulators of alpha-1 antitrypsin | SERPINA2, SERPINC1, SERPINA3 | CDC7 3618/4885HTR2A 3839/4885HTR2C 4262/4885 |
| US-20210179587-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | SERPINA2, SERPINA3, SERPINB1 | CDC7 3537/4885HTR2A 4721/4885HTR2C 4848/4885 |
| US-20240002386-A1 | SOLID FORMS OF 4-(5-(4-FLUOROPHENYL)-6-(TETRAHYDRO-2H-PYRAN-4-YL)-1,5-DIHYDROPYRROLO[2,3-F]INDAZOL-7-YL)BENZOIC ACID | SERPINA2, SERPINE1, SERPINH1 | CDC7 3727/4885HTR2A 4817/4885HTR2C 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.